Vicore Pharma Holding AB

Vicore Pharma Holding AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Vicore is a rare disease pharmaceutical company focused on rare lung disorders and related indications. The company currently has three drug development programs, VP01, VP02 and VP03.VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”), pulmonary fibrosis in systemic sclerosis (“SSc”) and COVID-19. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which have a significant unmet need. VP03 includes follow-up molecules to VP01. The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Interim report April-June 2019

Fri, Aug 23, 2019 08:00 CET

Mölndal, August 23, 2019 – Vicore Pharma Holding (publ) publish the interim report for the second quarter 2019.Important events during the second quarter · In April, Vicore Pharma announced that it has selected the disease diffuse systemic sclerosis (dSSc) as the second indication for its lead program VP01 (C21). It complements the primary indication, idiopathic pulmonary fibrosis (IPF) Important events after the period · No significant events have taken place after the period. Financial overview for the periodApril 1 - June 30, 2019 · Operating income amounted to 0.0

Interim report January - March 2019

Wed, May 15, 2019 08:00 CET

Mölndal, May 15, 2019 – Vicore Pharma Holding (publ) publishes the interim report for the first quarter 2018.Important events during the first quarter · In January, the directed share issue of approximately 160 MSEK was approved by an Extraordinary General Meeting. The total number of shares after the share issue amounts to 42,374,714. Important events after the period · Vicore Pharma announced on April 23 that it has selected the disease diffuse systemic sclerosis (dSSc) as the second indication for its lead program VP01 (C21). It complements the primary indication, idiopathic

Interim report April-June 2018

Fri, Aug 24, 2018 09:00 CET

Vicore Pharma Holding (publ) (ticker: VICO) publish the interim report for the second quarter 2018.Important events during the second quarter · In April, Vicore Pharma received approval to start a Phase IIa study in IPF · In May, Vicore Pharma Holding’s financial asset, I-Tech AB (publ), issued new shares in conjunction with the company’s share listing on Nasdaq First North Important events after the period · In July, Vicore Pharma Holding announced it had entered into an agreement to acquire INIM Pharma AB, a Swedish biopharmaceutical company developing a new local

Interim report January-March 2018

Tue, May 08, 2018 09:00 CET

Vicore Pharma Holding (publ) (ticker: VICO) publish the interim report for the first quarter 2018.IMPORTANT EVENTS DURING THE FIRST QUARTER · In February, Vicore Pharma Holding acquired additional shares from an existing shareholder in I-Tech. As such, our holding amounted to 26.5%. In March, I-Tech issued shares to a new shareholder, Cambrex Karlskoga AB. Vicore Pharma Holding’s holding is consequently 21.2%. IMPORTANT EVENTS AFTER THE PERIOD · In April Vicore Pharma holds approval from the UK authorities and the Ethics Committee to initiate a Phase IIa Study on Idiopathic

Interim report July-September 2017

Thu, Oct 19, 2017 08:00 CET

Vicore Pharma Holding publish the interim report for the third quarter, 2017.Important events during the third quarter 2017 · In August, the initial analysis of the results of the Phase I extension study was presented. The results verified that C21 is well tolerated and safe in a group with a potentially compromised metabolic situation. In addition, the study indicated positive effects on lipid metabolism. Important events after the period · In October, data from the in-depth analysis of the Phase I extension study was presented. The analysis strengthens previously published

There are no items matching the current filter

There are no more items matching the current filter

Share